Analyst Conference Summaries

Biotechnology Investor Aids

Reata Pharmaceuticals
RETA

conference date: August 9, 2021 @ 1:30 PM Pacific Time

Reata Bardoxolone Trial Success Likely, But Still Just A Hold [May 24, 2019 at Seeking Alpha]

Reata Pharmaceuticals a Buy [Feb. 14, 2018 at Seeking Alpha]

2021
Reata
Pharmaceuticals
Q4 2020
Reata
Pharmaceuticals
Q1 2021
Reata
Pharmaceuticals
Q2 2021
 
March 1, 2021 May 6, 2021 Aug. 9, 2021  
2020
Reata
Pharmaceuticals
Q4 2019
Reata
Pharmaceuticals
Q1 2020
Reata
Pharmaceuticals
Q2 2020
Reata
Pharmaceuticals
Q3 2020
Feb. 19, 2020 May 11, 2020 Aug. 10, 2020 Nov. 9, 2020
2019
Reata
Pharmaceuticals
Q4 2018
Reata
Pharmaceuticals
Q1 2019
Reata
Pharmaceuticals
Q2 2019
Reata
Pharmaceuticals
Q3 2019
Feb. 28, 2019 May 9, 2019 Aug. 8, 2019 Nov. 12, 2019
2018
March 2, 2018
May 9, 2018
August 8, 2018
Nov. 7, 2018

Reata Pharmaceuticals (RETA) is a clinical-stage biotechnology company specializing in therapies to improve mitochondrial functions for rate diseases, including chronic kidney diseases.

Reata Pharmaceutical web site


 

Search

More Analyst Conference Pages:

 AGEN
 AGIO
 ALNY
 ALXN
 AMAT
 AMGN
 APRE
 ARWR
 BIIB
 BMY
 CLDX
 CLSN
 EPZM
 GILD
 GLYC
 INCY
 INO
 IONS
 ISRG
 MCHP
 MRNA
 PLX
 REGN
 SGEN
 SYRS
 TTPH
 VBLT
 VSTM
 XLNX
 XLRN
     
 

Disclaimer: My analyst summaries may include both condensations of statements made by company representatives and my own analysis. They are not covered by any warranty. I cannot guarantee anything said by company representatives is true. I try not to make errors, but it is possible. These are my personal notes which I share with other investors and which I use as the basis of my blog and Seeking Alpha articles.

Copyright 2020 William P. Meyers